Since the introduction of the anti-vascular endothelial growth factor (anti-VEGF) intravitreal drugs, these therapies have become the mainstay of treatment for neovascular age-related macular degeneration (AMD).
The American Academy of Ophthalmology’s (AAO) Preferred Practice Pattern on Age-Related Macular Degeneration “are based on the best available scientific data as interpreted by panels of knowledgeable health professionals.”1 The recent version was updated in 2015. Here are its main points:
The AAO notes that while an estimated 80% of patients with AMD have non-neovascular or atrophic AMD, the neovascular form is responsible for nearly 90% of the severe central visual acuity loss associated with AMD. AMD is characterized by the presence of at least intermediate-size drusen (63 µm or larger), retinal pigment epithelium (RPE) abnormalities (such as hypopigmentation or hyperpigmentation), reticular pseudodrusen, among others.
AAO uses a combination of the Age-Related Eye Disease Study (AREDS) and a separate clinical classification to define the stages of AMD since current treatment recommendations also follow those classifications.